<- Go Home
Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.
Market Cap
$8.2B
Volume
597.7K
Cash and Equivalents
$809.1M
EBITDA
$78.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$287.3M
Profit Margin
47.70%
52 Week High
$211.13
52 Week Low
$110.45
Dividend
N/A
Price / Book Value
4.14
Price / Earnings
-4.3K
Price / Tangible Book Value
13.24
Enterprise Value
$8.2B
Enterprise Value / EBITDA
78.57
Operating Income
$8.4M
Return on Equity
-0.10%
Return on Assets
0.19
Cash and Short Term Investments
$809.1M
Debt
$742.9M
Equity
$2.0B
Revenue
$602.4M
Unlevered FCF
$123.3M
Sector
Life Sciences Tools and Services
Category
N/A